MedTrace Logo

A Study For Pregabalin In Patients With Fibromyalgia

NCT01387607 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 343

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and tolerability of pregabalin compared with placebo for management of fibromyalgia in adults.

Conditions

  • Fibromyalgia

Interventions

DRUG

pregabalin

Pregabalin capsule, 300-450mg/day, twice daily

DRUG

placebo

Placebo, twice daily

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-06
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01387607 on ClinicalTrials.gov